A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

NCT06682806 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Advanced Solid Tumor
Esophageal Cancer
Metastatic Solid Tumor
Non-small Cell Lung Cancers
SMARCA4 Gene Mutation

Interventions

DRUG: PRT3789
DRUG: pembrolizumab

Sponsor

Prelude Therapeutics

Collaborators

Merck Sharp & Dohme LLC